 Fulcrum ANNUAL REPORT AND ACCOUNTS 2008
1
HIGHLIGHTS
Revenue growth of 29% to £14.8m (2007: £11.5m)
Operating profit increased 258% to £666,000 (2007: £186,000)
Cash position strong at £2,903,000 (2007: £2,217,000)
EBITDA* doubled to £1,139,000 (2007: £573,000)
New Chief Executive, Chairman designate and non-executive Directors appointed
*
EBITDA is defined as earnings before interest, taxation, depreciation and amortisation
Our Vision
Fulcrum Pharma will be the most admired, pioneering and leading professional service company
in our selected fields.
